Kuros Biosciences AG / Key word(s): Miscellaneous
16-Feb-2023 / 18:01 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.
Ad hoc announcement pursuant to Article 53 of the SIX listing rules
New Chief Financial Officer (CFO) ad interim
Schlieren (Zurich), Switzerland, 16 February 2023 – Kuros Biosciences (“Kuros” or the “Company”), a leader in next generation bone graft technologies, announced today the appointment of Daniel Geiger as Chief Financial Officer (CFO) ad interim, effective February 17, 2023. Daniel Geiger succeeds Michael Grau, who will handover his CFO position.
Joost de Brujin, Chief Executive Officer of Kuros, said: “We are honoured to welcome Daniel Geiger to our executive team. Daniel is a seasoned financial executive with more than 20 years of international experience in the public listed domain including life sciences. He brings with him extensive expertise in finance transformation, M&A, public offerings, capital market transactions and investor relations, and is a valuable addition to our senior leadership team. I would also like to extend our sincerest thanks to Michael Grau for his tireless work and dedication over the last five years. He has been instrumental in our development of Kuros into a leading commercial-stage orthobiologics company, and we wish him well for the future.”
Daniel Geiger is certified as an Investor Relations Officer (CIRO) and Swiss Public Accountant (CPA) and has most recently joined Hoffmann & Partner as an Associate Partner providing executive CFO advisory, finance transformation and capital markets consulting services. Prior to that he was acting as Chief Accounting Officer and Vice President of Finance at the biopharmaceutical company Autolus, supporting the company on his transition from R&D to commercial.
Furthermore, Daniel Geiger spent six years at the Swiss Steel Group overseeing corporate accounting, controlling and investor relations, and before that he was acting as a CFO for EMEA and Vice President of Finance at software developer Kofax. He began his career as a Senior Audit Manager at Ernst & Young and holds a Bachelor’s in Accounting & Controlling and Information Technology from Fachhochschule Nordwestschweiz (FHNW) and an executive MBA from the University of Zurich.
For further information, please contact:
About Kuros Biosciences
Forward Looking Statements
End of Inside Information
|Company:||Kuros Biosciences AG|
|Phone:||+41 44 733 4747|
|Fax:||+41 44 733 4740|
|Listed:||SIX Swiss Exchange|
|EQS News ID:||1562197|
|End of Announcement||EQS News Service|